Gould B A, Mann S, Kieso H, Subramanian V B, Raftery E B
Circulation. 1982 Jan;65(1):22-7. doi: 10.1161/01.cir.65.1.22.
The blood pressure response in hypertensive subjects to chronic treatment with verapamil, a calcium antagonist (or, more precisely, a slow-channel inhibitor), was studied using the Oxford system for continuous monitoring of intraarterial blood pressure. Sixteen patients underwent continuous monitoring over a 48-hour period before and after at least 6 weeks of therapy (dose range 120-160 mg three times daily). Each monitoring period included physiologic tests designed to show the effects of different types of exercise. Verapamil produces a consistent reduction of blood pressure over 24 hours, but particularly during the day. Heart rate was similarly reduced. There was no evidence of postural hypotension, and the absolute responses to dynamic and isometric exercise were reduced. The degree of reduction of the blood pressure was consistent, suggesting that slow-channel inhibitors may be appropriate for antihypertensive therapy.
使用牛津系统对动脉内血压进行连续监测,研究了高血压患者对钙拮抗剂(或更准确地说,慢通道抑制剂)维拉帕米进行长期治疗时的血压反应。16名患者在至少6周治疗(剂量范围为每日三次,每次120 - 160毫克)前后,进行了48小时的连续监测。每个监测期都包括旨在显示不同类型运动效果的生理测试。维拉帕米可使血压在24小时内持续降低,尤其是在白天。心率也有类似降低。没有体位性低血压的证据,对动态和等长运动的绝对反应降低。血压降低程度一致,表明慢通道抑制剂可能适用于抗高血压治疗。